Regular monitoring of FVIII-specific antibodies as well as the very low-titer inhibitors by using the NusBA may help to identify patients at risk for developing inhibitors and tailor treatment based on the antibody spectrum present in persons with hemophilia A. The gene discussed is F8; the disease is hemophilia A.